The Impact of Surgical Margin Distance on Local Recurrence and Survival in Patients with Soft Tissue Sarcoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Patients
2.3. Pathology Protocol
2.4. Treatments
2.5. Variables
2.6. Primary and Secondary Study Outcomes
2.7. Ethical Approval
2.8. Statistical Analysis
3. Results
3.1. Study Population
3.2. Relationship Between Margin and Local Recurrence
3.3. Relationship Between Factors Other than Margin and Local Recurrence
3.4. Relationship Between Margin and Overall Survival
3.5. Relationship Between Factors Other than Margin and Overall Survival
3.6. Relationship Between Tumor Grade, Local Recurrence, and Overall Survival
4. Discussion
Reference | Year | Number of Patients | Sarcoma Site | Margin Categories (mm) | Local Recurrence (%) | Follow-Up, Months | Comments |
---|---|---|---|---|---|---|---|
Fujiwara et al. [30] | 2020 | 109 | Low-grade | Positive Negative with a margin of 0.1–1.9 mm Negative with a margin ≥ 2.0 mm | 38 8 0 | Median: 67 (39–103) | While the negative margin resulted in 90% local control, excellent local control was achieved with margins of ≥2 mm. |
Fujiwara et al. [15] | 2020 | 305 | High-grade nonmetastatic MFS or UPS | Positive 0.1 −0.9 1.0 −1.9 2.0 −4.9 5.0–9.9 >10 | 19 13 6 15 17 3 | Minimum: 24.0 | A margin distance of at least 10 mm is advocated for MFS and UPS to minimize the risk of LR. |
Gundle et al. [26] | 2018 | 2217 | Nonmetastatic extremity and trunk STS | R + 1 mm classification Gross Positive (R2) <1 >1 | 38.0 10.0 6.0 (5-Year LR) | Mean 65 (0.3–309) | An R + 1 mm classification reduced LR differences between R1 and R0, suggesting that a negative but 1 mm margin may be adequate with multidisciplinary treatment. |
Kainhofer et al. [22] | 2016 | 113 | All sites | Positive <1 ≥1 | 36.7 38.3 12.0 | Mean: 68.5 (1.0–201.0) | Local control rates were superior after a minimal resection margin of 1 mm compared to R0 resections after the R-classification. |
Harati et al. [24] | 2017 | 643 | Extremities | 0.1 −0.9 1–5 ≥5 | 31.4 32.1 31.6 | Median: 64.8 | No difference in local recurrence when comparing different margin widths for negative margin resections. |
Ahmad et al. [27] | 2016 | 382 | Low-to-high grade, extremity and truncal STS with R0 or R1 resection | Positive ≤1 >1–5 >5 | 83 LRFS 90 LRFS 93 LRFS 100 LRFS | Median: 82 | The LRFS demonstrates superiority with any negative margin, yet there is no disparity in LRFS when comparing negative margin widths. |
Novais et al. [7] | 2010 | 248 | Primary intermediate- high-grade STS of the extremity | ≤2 2.1–20 >20 | 11.6 2.4 0.0 | Median: 52.8 (4.8–156) | Margin > 2 mm recommended |
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
STS | soft tissue sarcomas |
FNCLCC | the French Federation Nationale des Centers de Lutte Contre le Cancer |
LRFS | local recurrence-free survival |
DFS | disease-free survival |
MRI | magnetic resonance imaging |
UPS | undifferentiated pleomorphic sarcoma |
MFS | myxofibrosarcoma |
RT | radiotherapy |
References
- Brownstein, J.M.; DeLaney, T.F. Malignant Soft-Tissue Sarcomas. Hematol. Oncol. Clin. N. Am. 2020, 34, 161–175. [Google Scholar] [CrossRef] [PubMed]
- Potter, B.K.; Hwang, P.F.; Forsberg, J.A.; Hampton, C.B.; Graybill, J.C.; Peoples, G.E.; Stojadinovic, A. Impact of margin status and local recurrence on soft-tissue sarcoma outcomes. J. Bone Jt. Surg. Am. 2013, 95, e151. [Google Scholar] [CrossRef]
- Choi, J.H.; Ro, J.Y. The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv. Anat. Pathol. 2021, 28, 44–58. [Google Scholar] [CrossRef] [PubMed]
- Gronchi, A.; Miah, A.B.; Dei Tos, A.P.; Abecassis, N.; Bajpai, J.; Bauer, S.; Biagini, R.; Bielack, S.; Blay, J.Y.; Bolle, S.; et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021, 32, 1348–1365. [Google Scholar] [CrossRef]
- Serban, B.; Cretu, B.; Cursaru, A.; Nitipir, C.; Orlov-Slavu, C.; Cirstoiu, C. Local recurrence management of extremity soft tissue sarcoma. EFORT Open Rev. 2023, 8, 606–614. [Google Scholar] [CrossRef] [PubMed]
- Yurtbay, A.; Coşkun, H.S.; Say, F.; Dabak, N. Is the Thickness of the Margin Associated with Local Recurrence and Survival in Patients with Myxofibrosarcoma? Clin. Orthop. Relat. Res. 2023, 481, 2125–2136. [Google Scholar] [CrossRef] [PubMed]
- Novais, E.N.; Demiralp, B.; Alderete, J.; Larson, M.C.; Rose, P.S.; Sim, F.H. Do surgical margin and local recurrence influence survival in soft tissue sarcomas? Clin. Orthop. Relat. Res. 2010, 468, 3003–3011. [Google Scholar] [CrossRef]
- Sugiura, H.; Tsukushi, S.; Yoshida, M.; Nishida, Y. What Is the Success of Repeat Surgical Treatment of a Local Recurrence After Initial Wide Resection of Soft Tissue Sarcomas? Clin. Orthop. Relat. Res. 2018, 476, 1791–1800. [Google Scholar] [CrossRef]
- Samà, L.; Binder, J.P.; Darrigues, L.; Couturaud, B.; Boura, B.; Helfre, S.; Chiche, L.; Nicolas, N.; Tzanis, D.; Bouhadiba, T.; et al. Safe-margin surgery by plastic reconstruction in extremities or parietal trunk soft tissue sarcoma: A tertiary single centre experience. Eur. J. Surg. Oncol. 2022, 48, 526–532. [Google Scholar] [CrossRef] [PubMed]
- Hoang, K.; Gao, Y.; Miller, B.J. The Variability in Surgical Margin Reporting in Limb Salvage Surgery for Sarcoma. Iowa Orthop. J. 2015, 35, 181–186. [Google Scholar]
- Enneking, W.F.; Spanier, S.S.; Goodman, M.A. A system for the surgical staging of musculoskeletal sarcoma. Clin. Orthop. Relat. Res. 1980, 106–120. [Google Scholar] [CrossRef]
- Steffner, R.J.; Jang, E.S. Staging of Bone and Soft-tissue Sarcomas. J. Am. Acad. Orthop. Surg. 2018, 26, e269–e278. [Google Scholar] [CrossRef] [PubMed]
- McKee, M.D.; Liu, D.F.; Brooks, J.J.; Gibbs, J.F.; Driscoll, D.L.; Kraybill, W.G. The prognostic significance of margin width for extremity and trunk sarcoma. J. Surg. Oncol. 2004, 85, 68–76. [Google Scholar] [CrossRef]
- Bilgeri, A.; Klein, A.; Lindner, L.H.; Nachbichler, S.; Knösel, T.; Birkenmaier, C.; Jansson, V.; Baur-Melnyk, A.; Dürr, H.R. The Effect of Resection Margin on Local Recurrence and Survival in High Grade Soft Tissue Sarcoma of the Extremities: How Far Is Far Enough? Cancers 2020, 12, 2560. [Google Scholar] [CrossRef]
- Fujiwara, T.; Stevenson, J.; Parry, M.; Tsuda, Y.; Tsoi, K.; Jeys, L. What is an adequate margin for infiltrative soft-tissue sarcomas? Eur. J. Surg. Oncol. 2020, 46, 277–281. [Google Scholar] [CrossRef]
- Rosenberg, S.A.; Tepper, J.O.E.L.; Glatstein, E.L.I.; Costa, J.O.S.E.; Baker, A.L.A.N.; Brennam, M.; Demoss, E.V.; Seipp, C.; Sindelar, W.F.; Sugarbaker, P.A.U.L.; et al. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann. Surg. 1982, 196, 305–315. [Google Scholar] [CrossRef] [PubMed]
- Trojani, M.; Contesso, G.; Coindre, J.M.; Rouesse, J.; Bui, N.B.; de Mascarel, A.; Goussot, J.F.; David, M.; Bonichon, F.; Lagarde, C. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int. J. Cancer. 1984, 33, 37–42. [Google Scholar] [CrossRef]
- Dickinson, I.C.; Whitwell, D.J.; Battistuta, D.; Thompson, B.; Strobel, N.; Duggal, A.; Steadman, P. Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J. Surg. 2006, 76, 104–109. [Google Scholar] [CrossRef] [PubMed]
- Song, B.; Lee, K.; Lee, C.; Moon, K.C. Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Pathol. Int. 2018, 68, 509–516. [Google Scholar] [CrossRef]
- Quirion, J.C.; Johnson, S.R.; Kowalski, B.L.; Halpern, J.L.; Schwartz, H.S.; Holt, G.E.; Prieto-Granada, C.; Singh, R.; Cates, J.M.; Rubin, B.P.; et al. Surgical Margins in Musculoskeletal Sarcoma. JBJS Rev. 2024, 12, e23. [Google Scholar] [CrossRef] [PubMed]
- Trovik, C.S.; Skjeldal, S.; Bauer, H.; Rydholm, A.; Jebsen, N. Reliability of Margin Assessment after Surgery for Extremity Soft Tissue Sarcoma: The SSG Experience. Sarcoma 2012, 2012, 290698. [Google Scholar] [CrossRef] [PubMed]
- Kainhofer, V.; Smolle, M.A.; Szkandera, J.; Liegl-Atzwanger, B.; Maurer-Ertl, W.; Gerger, A.; Riedl, J.; Leithner, A. The width of resection margins influences local recurrence in soft tissue sarcoma patients. Eur. J. Surg. Oncol. 2016, 42, 899–906. [Google Scholar] [CrossRef] [PubMed]
- Sambri, A.; Caldari, E.; Fiore, M.; Zucchini, R.; Giannini, C.; Pirini, M.G.; Spinnato, P.; Cappelli, A.; Donati, D.M.; De Paolis, M. Margin Assessment in Soft Tissue Sarcomas: Review of the Literature. Cancers 2021, 13, 1687. [Google Scholar] [CrossRef] [PubMed]
- Harati, K.; Goertz, O.; Pieper, A.; Daigeler, A.; Joneidi-Jafari, H.; Niggemann, H.; Stricker, I.; Lehnhardt, M. Soft Tissue Sarcomas of the Extremities: Surgical Margins Can Be Close as Long as the Resected Tumor Has No Ink on It. Oncologist 2017, 22, 1400–1410. [Google Scholar] [CrossRef]
- Wittenberg, S.; Paraskevaidis, M.; Jarosch, A.; Flörcken, A.; Brandes, F.; Striefler, J.; Kaul, D.; Roohani, S.; Khakzad, T.; Märdian, S.; et al. Surgical Margins in Soft Tissue Sarcoma Management and Corresponding Local and Systemic Recurrence Rates: A Retrospective Study Covering 11 Years and 169 Patients in a Single Institution. Life 2022, 12, 1694. [Google Scholar] [CrossRef]
- Gundle, K.R.; Kafchinski, L.; Gupta, S.; Griffin, A.M.; Dickson, B.C.; Chung, P.W.; Catton, C.N.; O’Sullivan, B.; Wunder, J.S.; Ferguson, P.C. Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. J. Clin. Oncol. 2018, 36, 704–709. [Google Scholar] [CrossRef] [PubMed]
- Ahmad, R.; Jacobson, A.; Hornicek, F.; Haynes, A.B.; Choy, E.; Cote, G.; Nielsen, G.P.; Chen, Y.L.; DeLaney, T.F.; Mullen, J.T. The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated with Radiotherapy. Oncologist 2016, 21, 1269–1276. [Google Scholar] [CrossRef] [PubMed]
- Yoo, H.J.; Hong, S.H.; Kang, Y.; Choi, J.Y.; Moon, K.C.; Kim, H.S.; Han, I.; Yi, M.; Kang, H.S. MR imaging of myxofibrosarcoma and undifferentiated sarcoma with emphasis on tail sign; diagnostic and prognostic value. Eur. Radiol. 2014, 24, 1749–1757. [Google Scholar] [CrossRef] [PubMed]
- Dadrass, F.; Gusho, C.; Yang, F.; Culvern, C.; Bloom, J.; Fillingham, Y.; Colman, M.; Gitelis, S.; Blank, A. A clinicopathologic examination of myxofibrosarcoma. Do surgical margins significantly affect local recurrence rates in this infiltrative sarcoma subtype? J. Surg. Oncol. 2021, 123, 489–496. [Google Scholar] [CrossRef] [PubMed]
- Fujiwara, T.; Kaneuchi, Y.; Tsuda, Y.; Stevenson, J.; Parry, M.; Jeys, L. Low-grade soft-tissue sarcomas: What is an adequate margin for local disease control? Surg. Oncol. 2020, 35, 303–308. [Google Scholar] [CrossRef]
- Sawamura, C.; Matsumoto, S.; Shimoji, T.; Tanizawa, T.; Ae, K. What are risk factors for local recurrence of deep high-grade soft-tissue sarcomas? Clin. Orthop. Relat. Res. 2012, 470, 700–705. [Google Scholar] [CrossRef] [PubMed]
- Tsagozis, P.; Bauer, H.C.; Styring, E.; Trovik, C.S.; Zaikova, O.; Brosjö, O. Prognostic factors and follow-up strategy for superficial soft-tissue sarcomas: Analysis of 622 surgically treated patients from the scandinavian sarcoma group register. J. Surg. Oncol. 2015, 111, 951–956. [Google Scholar] [CrossRef]
- Yang, J.C.; Chang, A.E.; Baker, A.R.; Sindelar, W.F.; Danforth, D.N.; Topalian, S.L.; DeLaney, T.; Glatstein, E.; Steinberg, S.M.; Merino, M.J.; et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol. 1998, 16, 197–203. [Google Scholar] [CrossRef]
- Pisters, P.W.; Harrison, L.B.; Leung, D.H.; Woodruff, J.M.; Casper, E.S.; Brennan, M.F. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J. Clin. Oncol. 1996, 14, 859–868. [Google Scholar] [CrossRef] [PubMed]
- O’Sullivan, B.; Davis, A.M.; Turcotte, R.; Bell, R.; Catton, C.; Chabot, P.; Wunder, J.; Kandel, R.; Goddard, K.; Sadura, A.; et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 2002, 359, 2235–2241. [Google Scholar] [CrossRef]
- Tanaka, K.; Ozaki, T. Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn. J. Clin. Oncol. 2021, 51, 180–184. [Google Scholar] [CrossRef] [PubMed]
- Istl, A.C.; Ruck, J.M.; Morris, C.D.; Levin, A.S.; Meyer, C.F.; Johnston, F.M. Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS. J. Surg. Oncol. 2019, 119, 824–835. [Google Scholar] [CrossRef]
- Gronchi, A.; Verderio, P.; De Paoli, A.; Ferraro, A.; Tendero, O.; Majò, J.; Martin, J.; Comandone, A.; Grignani, G.; Pizzamiglio, S.; et al. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Ann. Oncol. 2013, 24, 817–823. [Google Scholar] [CrossRef] [PubMed]
- Baldini, E.H.; Le Cesne, A.; Trent, J.C. Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-Risk Extremity Soft Tissue Sarcoma. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 910–915. [Google Scholar] [CrossRef] [PubMed]
- Medrano-Guzmán, R.; Brener-Chaoul, M.; García-Ríos, L.E.; Luna-Castillo, M. Extremity soft tissue sarcoma: Does surgical margin impact survival? Cirugía Cir. 2023, 91, 810–815. [Google Scholar] [CrossRef]
- Paul, M.; Gupta, S.; Wagh, M.; Mathew, A.P.; Cherian, K.; George, P.S.; Augustine, P.; Nair, C.K. Effects of Revision Surgery and Surgical Margins on Outcome of Peripheral Soft Tissue Sarcomas: Experience from a Tertiary Cancer Care Centre. Gulf J. Oncolog. 2022, 1, 21–26. [Google Scholar] [PubMed]
- Koshy, M.; Rich, S.E.; Mohiuddin, M.M. Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: A SEER analysis. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 203–209. [Google Scholar] [CrossRef] [PubMed]
- Kungwengwe, G.; Clancy, R.; Vass, J.; Slade, R.; Sandhar, S.; Dobbs, T.D.; Bragg, T.W. Preoperative versus Post-operative Radiotherapy for Extremity Soft tissue Sarcoma: A Systematic Review and Meta-analysis of Long-term Survival. J. Plast. Reconstr. Aesthet. Surg. 2021, 74, 2443–2457. [Google Scholar] [CrossRef]
- Casali, P.G. Adjuvant chemotherapy for soft tissue sarcoma. Am. Soc. Clin. Oncol. Educ. Book 2015, 35, e629–e633. [Google Scholar] [CrossRef] [PubMed]
- Gronchi, A.; Palmerini, E.; Quagliuolo, V.; Martin Broto, J.; Lopez Pousa, A.; Grignani, G.; Brunello, A.; Blay, J.Y.; Tendero, O.; Diaz Beveridge, R.; et al. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J. Clin. Oncol. 2020, 38, 2178–2186. [Google Scholar] [CrossRef] [PubMed]
- Woll, P.J.; Reichardt, P.; Le Cesne, A.; Bonvalot, S.; Azzarelli, A.; Hoekstra, H.J.; Leahy, M.; Van Coevorden, F.; Verweij, J.; Hogendoorn, P.C.; et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial. Lancet Oncol. 2012, 13, 1045–1054. [Google Scholar] [CrossRef]
- Frustaci, S.; Gherlinzoni, F.; De Paoli, A.; Bonetti, M.; Azzarelli, A.; Comandone, A.; Olmi, P.; Buonadonna, A.; Pignatti, G.; Barbieri, E.; et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J. Clin. Oncol. 2001, 19, 1238–1247. [Google Scholar] [CrossRef]
- Liang, Y.; Guo, T.; Hong, D.; Xiao, W.; Zhou, Z.; Zhang, X. Time to Local Recurrence as a Predictor of Survival in Patients with Soft Tissue Sarcoma of the Extremity and Abdominothoracic Wall. Front. Oncol. 2020, 10, 599097. [Google Scholar] [CrossRef] [PubMed]
Tumor Type | Test Statistics | p | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
UPS | Liposarcoma | Myxofibrosarcoma | Synovial Sarcoma | Fibrosarcoma | Rhabdomyosarcoma | Leiomyosarcoma | Other Rare Sarcomas | |||
Sex | ||||||||||
Female | 28 (45.2) | 9 (34.6) | 10 (40) | 14 (70) | 9 (60) | 2 (16.7) | 4 (50) | 5 (29.4) | 13.197 | 0.062 * |
Male | 34 (54.8) | 17 (65.4) | 15 (60) | 6 (30) | 6 (40) | 10 (83.3) | 4 (50) | 12 (70.6) | ||
Tumor location | ||||||||||
Lower extremity | 43 (69.4) | 23 (88.5) | 17 (68) | 17 (85) | 12 (80) | 10 (83.3) | 8 (100) | 13 (76.5) | 7.955 | 0.313 * |
Upper extremity | 19 (30.6) | 3 (11.5) | 8 (32) | 3 (15) | 3 (20) | 2 (16.7) | 0 (0) | 4 (23.5) | ||
Histopathologic margin classification | ||||||||||
≤1 mm | 28 (45.2) | 9 (34.6) | 9 (36) | 11 (55) | 4 (26.7) | 5 (41.7) | 5 (62.5) | 4 (23.5) | 12.643 | 0.533 * |
>1 mm | 26 (41.9) | 12 (46.2) | 12 (48) | 5 (25) | 7 (46.7) | 7 (58.3) | 2 (25) | 9 (52.9) | ||
Positive | 8 (12.9) | 5 (19.2) | 4 (16) | 4 (20) | 4 (26.7) | 0 (0) | 1 (12.5) | 4 (23.5) | ||
Local recurrence | ||||||||||
No | 38 (61.3) | 18 (69.2) | 17 (68) | 12 (60) | 7 (46.7) | 8 (66.7) | 4 (50) | 7 (41.2) | 5.799 | 0.567 * |
Yes | 24 (38.7) | 8 (30.8) | 8 (32) | 8 (40) | 8 (53.3) | 4 (33.3) | 4 (50) | 10 (58.8) | ||
Metastasis | ||||||||||
No | 54 (87.1) | 26 (100) | 21 (84) | 15 (75) | 14 (93.3) | 10 (83.3) | 7 (87.5) | 14 (82.4) | 8.737 | 0.212 * |
Yes | 8 (12.9) | 0 (0) | 4 (16) | 5 (25) | 1 (6.7) | 2 (16.7) | 1 (12.5) | 3 (17.6) | ||
Depth | ||||||||||
Deep | 35 (56.5) | 12 (46.2) | 16 (64) | 11 (55) | 6 (40) | 3 (25) | 5 (62.5) | 8 (47.1) | 7.184 | 0.404 * |
Superficial | 27 (43.5) | 14 (53.8) | 9 (36) | 9 (45) | 9 (60) | 9 (75) | 3 (37.5) | 9 (52.9) | ||
Tumor grade | ||||||||||
1 | 2 (3.2) a | 6 (23) ab | 2 (8) ab | 1 (5) ab | 1 (6.7) ab | 3 (25) b | 1 (12.5) ab | 0 (0) ab | 21.02 | 0.040 * |
2 | 28 (45.2) | 12 (46.1) | 10 (40) | 7 (35) | 5 (33.3) | 4 (33.3) | 3 (37.5) | 9 (52.9) | ||
3 | 32 (51.6) | 8 (30.7) | 13 (52) | 12 (60) | 9 (60) | 5 (41.7) | 4 (50) | 8 (47.1) | ||
Amputation | ||||||||||
No | 57 (91.9) | 26 (100) | 24 (96) | 19 (95) | 15 (100) | 12 (100) | 8 (100) | 17 (100) | 3.851 | 0.781 * |
Yes | 5 (8.1) | 0 (0) | 1 (4) | 1 (5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
Prognosis | ||||||||||
DDU | 12 (19.4) | 3 (11.5) | 2 (8) | 3 (15) | 1 (6.7) | 1 (8.3) | 2 (25) | 0 (0) | 15.26 | 0.297 * |
DOD | 10 (16.1) | 1 (3.8) | 5 (20) | 4 (20) | 1 (6.7) | 4 (33.3) | 2 (25) | 3 (17.6) | ||
NED | 40 (64.5) | 22 (84.6) | 18 (72) | 13 (65) | 13 (86.7) | 7 (58.3) | 4 (50) | 14 (82.4) | ||
Adjuvant therapy ~ | ||||||||||
CTX | 24 (38.8) a | 5 (19.2) bc | 5 (20) b | 7 (35) c | 4 (26.7) | 8 (66.6) | 1 (12.5) | 6 (35.3) | 110.197 | <0.001 ** |
RT | 56 (90.3) ac | 19 (73.1) a | 23 (92) | 18 (90) ab | 12 (80) | 9 (75) b | 5 (62.5) bcd | 13 (76.4) ad |
Age | Overall Survival | Local Recurrence Free Time | Tumor Size | Tumor Grade | |
---|---|---|---|---|---|
Tumor type | |||||
UPS (n = 62) | 59.19 ± 19.98 | 51.81 ± 36.51 | 36.82 ± 38.35 | 9.92 ± 5.49 | 2.48 ± 0.5 |
62.5 (14–86) cd | 33 (24–148) | 24.5 (1–148) | 8 (2–25) | 3 (1–3) | |
Liposarcoma (n = 26) | 46.16 ± 21.2 | 65.38 ± 33.69 | 47.23 ± 38.89 | 10.96 ± 7.48 | 2.08 ± 0.5 |
45 (2–77) abc | 73 (24–120) | 26.5 (3–109) | 10.5 (3–36) | 2 (1–3) | |
Myxofibrosarcoma (n = 25) | 63.96 ± 14.96 | 52.08 ± 32.28 | 43.84 ± 39.44 | 10.8 ± 6.22 | 1.92 ± 0.65 |
65 (35–85) bc | 39 (24–128) | 34 (1–128) | 10 (2–25) | 3 (1–3) | |
Synovial sarcoma (n = 20) | 47.5 ± 25.7 | 53.05 ± 30.03 | 34.05 ± 33.43 | 9.3 ± 5.82 | 2.5 ± 0.5 |
45 (4–85) abc | 48 (24–132) | 24 (2–110) | 7 (3–26) | 3 (1–3) | |
Fibrosarcoma (n = 15) | 37.8 ± 16.48 | 71.07 ± 19.93 | 41.4 ± 32.01 | 7.27 ± 3.22 | 2.5 ± 0.51 |
31 (23–73) a | 66 (48–110) | 42 (3–108) | 6 (4–14) | 3 (1–3) | |
Rhabdomyosarcoma (n = 12) | 19.91 ± 25.06 | 64.42 ± 54.63 | 52.58 ± 58.93 | 7.83 ± 2.25 | 2.08 ± 0.9 |
7 (3–73) a | 36 (24–168) | 26 (3–168) | 8 (4–11) | 2 (1–3) | |
Leiomyosarcoma (n = 8) | 58.75 ± 25.59 | 60.5 ± 43.04 | 40.5 ± 38.94 | 9.75 ± 4.53 | 2.38 ± 0.52 |
55 (24–95) abc | 43.5 (24–132) | 24.5 (5–108) | 8 (5–17) | 3 (1–3) | |
Other rare sarcomas (n = 17) | 41.24 ± 21.34 | 59.94 ± 36.78 | 31.53 ± 41.32 | 7.59 ± 5.41 | 2.47 ± 0.51 |
46 (4–68) ad | 48 (24–144) | 16 (2–144) | 6 (3–22) | 2 (2–3) | |
Test Statistics | 39.186 | 9.863 | 4.669 | 9.019 | 5.300 |
p * | <0.001 | 0.196 | 0.700 | 0.251 | 0.623 |
Local Recurrence | Univariate | Multiple | ||||
---|---|---|---|---|---|---|
Negative | Positive | HR (%95 CI) | p | HR (%95 CI) | p | |
Tumor type | ||||||
Liposarcoma | 18 (69.2) | 8 (30.8) | ||||
UPS | 38 (61.3) | 24 (38.7) | 1.351 (0.607–3.007) | 0.461 | 2.983 (1.134–7.842) | 0.027 |
Myxofibrosarcoma | 17 (68) | 8 (32) | 1.141 (0.428–3.042) | 0.792 | 3.697 (1.14–11.987) | 0.029 |
Synovial sarcoma | 12 (60) | 8 (40) | 1.524 (0.572–4.062) | 0.400 | 2.79 (0.879–8.855) | 0.082 |
Fibrosarcoma | 7 (46.7) | 8 (53.3) | 1.74 (0.653–4.637) | 0.268 | 2.029 (0.67–6.151) | 0.211 |
Rhabdomyosarcoma | 8 (66.7) | 4 (33.3) | 1.08 (0.325–3.587) | 0.900 | 7.403 (1.86–29.464) | 0.005 |
Leiomyosarcoma | 4 (50) | 4 (50) | 1.723 (0.519–5.722) | 0.375 | 2.319 (0.57–9.444) | 0.240 |
Other rare sarcomas | 7 (41.2) | 10 (58.8) | 2.357 (0.929–5.976) | 0.071 | 5.423 (1.809–16.25) | 0.003 |
Sex | ||||||
Female | 54 (66.7) | 27 (33.3) | ||||
Male | 57 (54.8) | 47 (45.2) | 1.492 (0.929–2.396) | 0.098 | 1.08 (0.601–1.942) | 0.796 |
Tumor location | ||||||
Lower extremity | 89 (62.2) | 54 (37.8) | ||||
Upper extremity | 22 (52.4) | 20 (47.6) | 1.285 (0.769–2.147) | 0.338 | 0.647 (0.358–1.169) | 0.149 |
Histopathologic margin classification | ||||||
≤1 mm | 44 (58.7) | 31 (41.3) | ||||
>1 mm | 66 (82.5) | 14 (17.5) | 0.336 (0.178–0.632) | 0.001 | 0.408 (0.206–0.808) | 0.010 |
Positive | 1 (3.3) | 29 (96.7) | 7.026 (4.099–12.042) | <0.001 | 10.552 (5.264–21.152) | <0.001 |
Depth | ||||||
Deep | 46 (47.9) | 50 (52.1) | ||||
Superficial | 65 (73) | 24 (27) | 0.405 (0.248–0.659) | <0.001 | 0.527 (0.304–0.913) | 0.022 |
CTX | ||||||
No | 62 (49.6) | 63 (50.4) | ||||
CTX | 49 (81.7) | 11 (18.3) | 3.165 (1.829–6.135) | <0.001 | 1.165 (0.534–2.75) | 0.687 |
RT | ||||||
No | 22 (73.7) | 8 (26.7) | ||||
RT | 89 (57.4) | 66 (42.6) | 2.361 (1.378–4.125) | 0.005 | 1.414 (0.616–2.916) | 0.584 |
Age | 52.19 ± 22.8 | 49.16 ± 24.29 | 0.997 (0.987–1.007) | 0.554 | 0.989 (0.975–1.003) | 0.133 |
Tumor size | 8.74 ± 4.73 | 10.76 ± 6.68 | 1.05 (1.015–1.088) | 0.006 | 1.028 (0.982–1.076) | 0.231 |
Tumor grade | 2.3 ± 0.57 | 2.77 ± 0.42 | 3.926 (2.312–6.667) | <0.001 | 4.501 (2.57–7.883) | <0.001 |
Survival | Univariate | Multiple | ||||
---|---|---|---|---|---|---|
Alive | Dead | HR (%95 CI) | p | HR (%95 CI) | p | |
Tumor type | ||||||
Liposarcoma | 22 (84.6) | 4 (15.4) | ||||
UPS | 40 (64.5) | 22 (35.5) | 2.737 (0.932–8.031) | 0.067 | 1.913 (0.585–6.262) | 0.283 |
Myxofibrosarcoma | 18 (72) | 7 (28) | 2.474 (0.722–8.484) | 0.150 | 4.952 (1.214–20.201) | 0.026 |
Synovial sarcoma | 13 (65) | 7 (35) | 2.773 (0.806–9.544) | 0.106 | 3.904 (0.997–15.283) | 0.050 |
Fibrosarcoma | 13 (86.7) | 2 (13.3) | 0.821 (0.15–4.498) | 0.820 | 1.281 (0.218–7.51) | 0.784 |
Rhabdomyosarcoma | 7 (58.3) | 5 (41.7) | 2.124 (0.552–8.177) | 0.273 | 8.946 (2.037–39.289) | 0.004 |
Leiomyosarcoma | 4 (50) | 4 (50) | 3.191 (0.792–12.865) | 0.103 | 0.963 (0.159–5.83) | 0.967 |
Other rare sarcomas | 14 (82.4) | 3 (17.6) | 1.238 (0.276–5.542) | 0.780 | 1.263 (0.262–6.079) | 0.771 |
Sex | ||||||
Female | 62 (76.5) | 19 (23.5) | ||||
Male | 69 (66.3) | 35 (33.7) | 1.746 (0.996–3.062) | 0.052 | 1.471 (0.74–2.925) | 0.270 |
Tumor location | ||||||
Lower extremity | 101 (70.6) | 42 (29.4) | ||||
Upper extremity | 30 (71.4) | 12 (28.6) | 1.145 (0.597–2.196) | 0.684 | 1.055 (0.507–2.194) | 0.886 |
Histopathologic margin classification | ||||||
≤1 mm | 55 (73.3) | 20 (26.7) | ||||
>1 mm | 62 (77.5) | 18 (22.5) | 0.678 (0.355–1.297) | 0.240 | 1.304 (0.543–3.131) | 0.553 |
Positive | 14 (46.7) | 16 (53.3) | 2.632 (1.328–5.218) | 0.006 | 3.579 (1.456–8.798) | 0.005 |
Local recurrence | ||||||
No | 87 (78.4) | 24 (21.6) | ||||
Yes | 44 (59.5) | 30 (40.5) | 2.67 (1.538–4.636) | <0.001 | 1.892 (0.866–4.135) | 0.110 |
Depth | ||||||
Deep | 68 (70.8) | 28 (29.2) | ||||
Superficial | 63 (70.8) | 26 (29.2) | 0.96 (0.562–1.638) | 0.880 | 1.077 (0.511–2.271) | 0.846 |
CTX | ||||||
No | 90 (72) | 35 (28) | ||||
CTX | 41 (68.3) | 19 (31.7.) | 1.724 (0.914–3.745) | 0.096 | 1.593 (0.675–3.882) | 0.316 |
RT | ||||||
No | 21 (70) | 9 (30) | ||||
RT | 110 (71) | 45 (29) | 1.086 (0.645–1.956) | 0.767 | 0.319 (0.154–0.765) | 0.009 |
Age | 45.81 ± 21.56 | 63.33 ± 23.13 | 1.028 (1.015–1.041) | <0.001 | 1.034 (1.015–1.053) | <0.001 |
Tumor size | 8.66 ± 5.13 | 11.69 ± 6.34 | 1.047 (1.01–1.085) | 0.012 | 1.019 (0.97–1.071) | 0.452 |
Tumor grade | 2.38 ± 0.57 | 2.74 ± 0.44 | 2.922 (1.65–5.173) | <0.001 | 3.121 (1.518–6.413) | 0.002 |
Mean (Months) (%95 CI) | Test Statistics | p * | |
---|---|---|---|
Histopathologic margin classification | |||
≤1 mm | 87.422 (72.201–102.643) c | 140.2 | <0.001 |
>1 mm | 139.799 (126.343–153.255) b | ||
Positive | 7.233 (2.665–11.802) a | ||
Overall | 103.187 (91.732–114.641) |
Mean (%95 CI) | Test Statistics | p * | |
---|---|---|---|
Histopathologic margin classification | |||
≤1 mm | 103.948 (91.217–116.679) b | 16.723 | <0.001 |
>1 mm | 120.771 (104.593–136.949) b | ||
Positive | 65.151 (53.011–77.291) a | ||
Overall | 106.722 (95.985–117.46) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yurtbay, A.; Aydın Şimşek, Ş.; Cengiz, T.; Bariş, Y.S.; Say, F.; Dabak, N. The Impact of Surgical Margin Distance on Local Recurrence and Survival in Patients with Soft Tissue Sarcoma. Medicina 2025, 61, 289. https://doi.org/10.3390/medicina61020289
Yurtbay A, Aydın Şimşek Ş, Cengiz T, Bariş YS, Say F, Dabak N. The Impact of Surgical Margin Distance on Local Recurrence and Survival in Patients with Soft Tissue Sarcoma. Medicina. 2025; 61(2):289. https://doi.org/10.3390/medicina61020289
Chicago/Turabian StyleYurtbay, Alparslan, Şafak Aydın Şimşek, Tolgahan Cengiz, Yakup Sancar Bariş, Ferhat Say, and Nevzat Dabak. 2025. "The Impact of Surgical Margin Distance on Local Recurrence and Survival in Patients with Soft Tissue Sarcoma" Medicina 61, no. 2: 289. https://doi.org/10.3390/medicina61020289
APA StyleYurtbay, A., Aydın Şimşek, Ş., Cengiz, T., Bariş, Y. S., Say, F., & Dabak, N. (2025). The Impact of Surgical Margin Distance on Local Recurrence and Survival in Patients with Soft Tissue Sarcoma. Medicina, 61(2), 289. https://doi.org/10.3390/medicina61020289